Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02616029
Recruitment Status : Active, not recruiting
First Posted : November 26, 2015
Last Update Posted : May 14, 2019
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : October 11, 2018
  Estimated Study Completion Date : July 2019